Antitumor Effects of Newcastle Disease Virus Hemagglutinin-neuraminidase Used as a Molecular Adjuvant

doi:10.1007/s40242-013-2391-5

高等学校化学研究 ›› 2013, Vol. 29 ›› Issue (2): 270-274.doi: 10.1007/s40242-013-2391-5

Antitumor Effects of Newcastle Disease Virus Hemagglutinin-neuraminidase Used as a Molecular Adjuvant

JI Hui-fan^1,2, CHI Bao-rong¹, HE Dong-yun^1,2, LI Chang^2,3, HU Ning-ning², WANG Kai², SHENG Yuan², WANG Hong-yu², JIN Ning-yi^2,3

1. Department of Gastroenterology, the First Hospital of Jilin University, Changchun 130021, P. R. China;
2. Institute of Military Veterinary, Academy of Military Medical Sciences of PLA, Changchun 130122, P. R. China;
3. Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, P. R. China

收稿日期:2012-10-15 修回日期:2012-12-16 出版日期:2013-04-01 发布日期:2013-03-20
通讯作者: JIN Ning-yi E-mail:Ningyik@126.com
基金资助:
Supported by the National Science and Technology Major Projects for Major New Drugs Innovation and Development of China(No.2010ZX09401-305-14), the National Natural Science Foundation of China(Nos.81072210, 81101140) and the Key Technologies R&D Program of Jilin Province of China(Nos.10ZDGG007, 201015166, 201101066).

Antitumor Effects of Newcastle Disease Virus Hemagglutinin-neuraminidase Used as a Molecular Adjuvant

JI Hui-fan^1,2, CHI Bao-rong¹, HE Dong-yun^1,2, LI Chang^2,3, HU Ning-ning², WANG Kai², SHENG Yuan², WANG Hong-yu², JIN Ning-yi^2,3

1. Department of Gastroenterology, the First Hospital of Jilin University, Changchun 130021, P. R. China;
2. Institute of Military Veterinary, Academy of Military Medical Sciences of PLA, Changchun 130122, P. R. China;
3. Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, P. R. China

Received:2012-10-15 Revised:2012-12-16 Online:2013-04-01 Published:2013-03-20
Supported by:
Supported by the National Science and Technology Major Projects for Major New Drugs Innovation and Development of China(No.2010ZX09401-305-14), the National Natural Science Foundation of China(Nos.81072210, 81101140) and the Key Technologies R&D Program of Jilin Province of China(Nos.10ZDGG007, 201015166, 201101066).

摘要/Abstract

摘要：

Gene therapy is a potentially powerful tool used in cancer therapy. The strength of immune responses induced by some strategies is usually low, therefore, the development of agents capable of enhancing these responses is highlighted. The authors investigated the potential of an approach based on the hemagglutinin-neuraminidase(HN) of Newcastle disease virus(NDV) as a potential immune adjuvant. It was found that recombinant adenovirus(Ad) infected SGC7901 cells expressing HN exhibited both hemagglutinin(HA) and neuraminidase(NA) activities. It was demonstrated that administration of HN induced higher levels of the effector cytokines TNF-α, IFN-α and IFN-γ and increased natural killer(NK) cell activity. Based on the therapeutic tumor model, the results show that the administration of HN with Apoptin led to improved survival and tumor suppression. In conclusion, this study indicates that HN stimulates innate immune responses to make the activity of NK cells increased, which highlights the potential adjuvant activity of HN in cancer gene therapy.

关键词: Hemagglutinin-neuraminidase(HN), Adjuvant, Innate immunity, Natural killer cell, Antitumor immunity

Abstract:

Key words: Hemagglutinin-neuraminidase(HN), Adjuvant, Innate immunity, Natural killer cell, Antitumor immunity

JI Hui-fan, CHI Bao-rong, HE Dong-yun, LI Chang, HU Ning-ning, WANG Kai, SHENG Yuan, WANG Hong-yu, JIN Ning-yi. Antitumor Effects of Newcastle Disease Virus Hemagglutinin-neuraminidase Used as a Molecular Adjuvant[J]. 高等学校化学研究, 2013, 29(2): 270-274.

参考文献

[1] Li X., Liu Y., Wen Z. M., Li C., Lu H. J., Tian M. Y., Jin K. S., Sun L. L., Gao P., Yang E. C., Xu X. H., Kan S. F., Wang Z. M., Wang Y. H., Jin N. Y., Mol. Cancer, 2010, 20(9), 10

[2] Nia J., Galanib I., Cerwenkab A., Schirrmachera V., Fourniera P., Vaccine, 2011, 29(6), 1185

[3] Nia J., Schirrmachera V., Fourniera P., Vaccine, 2010, 28(42), 6891

[4] Su J. Q., Chi B. R., Li X., Liu L., Liu L. M., Qi Y. X., Wang Z. Y., Jin N. Y., Chem. Res. Chinese Universities, 2012, 28(3), 465

[5] Liu L., Wu W. B., Zhu G. Z., Liu L. M., Guan G. F., Jin N. Y., Chi B. R., Li X., Int. J. Mol. Med., 2012, 10, 3892

[6] Piao B. G., Li X., Sun L. L., Kan S. F., Liu L., Huang H. Y., Yang G. H., Wang Y. H., Wang Z. Y., Sun J. H., Piao Y. F., Jin N. Y., Chem. Res. Chinese Universities, 2011, 27(3), 455

[7] Lech P. J., Russell S. J., Expert. Rev. Vaccines, 2010, 9(11), 1275

[8] Scheid A., Choppin P. W.,J. Virol., 1973, 11(2), 263

[9] Liu C., Air G. M., Virology, 1993, 194(1), 403

[10] Fournier P., Zeng J., von der Lieth C. W., Washburn B., Ahlert T., Schirrmacher V., Int. J. Oncol., 2004,24(3), 623

[11] Jarahian M., Watzl C., Fournier P., Arnold A., Djandji D., Zahedi S., Cerwenka A., Paschen A., Schirrmacher V., Momburg F., J. Virol., 2009, 83(16), 8108

[12] Zeng J., Fournier P., Schirrmacher V., Virology, 2002, 297(1), 19

[13] McKee A. S., Munks M. W., Marrack P., Immunity, 2007, 27(5), 687

[14] Zhang X., Yu C., Zhao J., Fu L., Yi S., Liu S., Yu T., Chen W., J. Gene Med., 2007, 9(8), 715

[15] Lo-Man R., Rueda P., Sedlik C., Deriaud E., Casal I., Leclerc C., Eur. J. Immunol., 1998, 28(4), 1401

[16] Takahashi H., Takeshita T., Morein B., Putney S., Germain R. N., Berzofsky J. A., Nature, 1990, 344(6269), 873

[17] Medzhitov R., Janeway C. A. Jr., Curr. Opin. Immunol., 1997, 9(1), 4

[18] Davis I. D., Immunol. Cell Biol., 2000, 78(3), 179

[19] Haeryfar S. M. M., Arch. Iranian. Med., 2008, 11(2), 186

[20] Cheng M., Zhang J., Jiang W., Chen Y. Y., Tian Z. G., Front. Med., 2012, 6(1), 56

[21] Sutlu T., Alici E., J. Intern. Med., 2009, 266(2), 154

[22] Bryceson Y. T., March M. E., Ljunggren H. G., Long E. O., Immunol. Rev., 2006, 214(1), 73

[23] Martín-Fontecha A., Thomsen L. L., Brett S., Gerard C., Lipp M., Lanzavecchia A., Sallusto F., Nat. Immunol., 2004, 5(12), 1260

Antitumor Effects of Newcastle Disease Virus Hemagglutinin-neuraminidase Used as a Molecular Adjuvant

Antitumor Effects of Newcastle Disease Virus Hemagglutinin-neuraminidase Used as a Molecular Adjuvant

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	HUANG Hai-yan, MENG Xiang-wei, LI Xiao, SUN Li-li, KAN Shi-fu, LIU Lei, PIAO Bin. Induction of Effective Antitumor Immune Response by Combined Administration of hIL-18 and NDV HN[J]. 高等学校化学研究, 2011, 27(5): 836-840.
[2]	GUO Xiu-xia1,2, YAN Liang2, YANG Yi2, YUAN Ruo-sen2, LIU Yan2 and SHENG Jun1,2*. Immunization Schedule of Liposomal Rabies Vaccine in Animals[J]. 高等学校化学研究, 2010, 26(5): 810-815.
[3]	JIANG Chun-lai, YU Xiang-hui, WU Yong-ge, LI Wei, KONG Wei. Co-administration of Interleukin-2 Enhances Cellular and Humoral Immune Responses to HIV Vaccine DNA Prime/MVA Boost Regime[J]. 高等学校化学研究, 2005, 21(3): 287-290.